{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T13:17:54Z","timestamp":1781011074638,"version":"3.54.1"},"reference-count":32,"publisher":"American Academy of Pediatrics (AAP)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2009,2,1]]},"abstract":"<jats:p>BACKGROUND. Brimonidine tartrate, a centrally acting selective \u03b1-2 adrenergic agonist with a toxicity that is often compared with that of clonidine, is used as eye drops to lower intraocular pressure in glaucoma. We investigated characteristics of childhood exposures to brimonidine-containing products.<\/jats:p>\n               <jats:p>METHODS. All brimonidine exposures in children 0 to 5 years of age between 1997 and 2005 were retrieved from the American Association of Poison Control Centers' Toxic Exposure Surveillance System database and the US Food and Drug Administration's Medwatch Adverse Events Reporting System. The design of the study was retrospective, and the main outcome measures were frequency of exposures over time, reason, symptoms\/signs of toxicity, dose, management site, treatment, and outcome.<\/jats:p>\n               <jats:p>RESULTS. There were 413 brimonidine reports in the Toxic Exposure Surveillance System and 340 in the Adverse Events Reporting System during the 9 years under study, of which 185 Toxic Exposure Surveillance System reports involved children \u22645 years of age versus 15 cases in the Adverse Events Reporting System. There were no deaths. The peak age of poisoning in the Toxic Exposure Surveillance System pediatric cases was 2 years of age, and circumstances were unintentional poisoning in 176 cases, usually by ingestion (84.3%). Common symptoms in 176 children included drowsiness (40.9%), ataxia (4.5%), pallor (4.5%), irritability (4.0%), hypotension (4.0%), bradycardia (4.0%), miosis (3.4%), and respiratory depression (3.4%). Of the 176 unintentional pediatric poisonings, 73 children were observed at home and 103 were seen at a health care facility; 28 were hospitalized and 11 received naloxone. Of the 15 pediatric cases in the Adverse Events Reporting System data set, all were hospitalized, and 13 had ocular exposures only.<\/jats:p>\n               <jats:p>CONCLUSIONS. All children \u22645 years of age with confirmed brimonidine ingestions should be medically evaluated and monitored for an extended period. Indications for the use of naloxone in brimonidine poisoning remain uncertain.<\/jats:p>","DOI":"10.1542\/peds.2008-1951","type":"journal-article","created":{"date-parts":[[2009,1,6]],"date-time":"2009-01-06T01:33:34Z","timestamp":1231205614000},"page":"e305-e311","source":"Crossref","is-referenced-by-count":25,"title":["Brimonidine Tartrate Poisoning in Children: Frequency, Trends, and Use of Naloxone as an Antidote"],"prefix":"10.1542","volume":"123","author":[{"given":"Melisa Lai","family":"Becker","sequence":"first","affiliation":[{"name":"Division of Emergency Medicine, Cambridge Hospital, Cambridge, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noelle","family":"Huntington","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Harvard Medical School, Boston, Massachusetts"},{"name":"Division of General Pediatrics"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan D.","family":"Woolf","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Harvard Medical School, Boston, Massachusetts"},{"name":"Division of General Pediatrics"},{"name":"Pediatric Environmental Health Center, Children's Hospital Boston, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"417","published-online":{"date-parts":[[2009,2,1]]},"reference":[{"key":"2021120822560191100_R1","unstructured":"Alphagan-P [package insert]. Irvine, CA: Allergan Incorporated; 2007"},{"key":"2021120822560191100_R2","unstructured":"Anonymous. Brimonidine: an alpha-2 agonist for glaucoma. Med Lett Drugs Ther.\u20081997;39(1002):54\u201355"},{"key":"2021120822560191100_R3","unstructured":"Anonymous. NDC Health Pharmaceutical Audit Suite (PHAST) Prescription Monthly. Available at: www.RXlist.com\/script\/main\/hp.asp. Accessed December 12, 2008"},{"key":"2021120822560191100_R4","doi-asserted-by":"crossref","unstructured":"Klein-Schwartz W. Trends and toxic effects from pediatric clonidine exposures. Arch Pediatr Adolesc Med.\u20082002;156(4):392\u2013396","DOI":"10.1001\/archpedi.156.4.392"},{"key":"2021120822560191100_R5","doi-asserted-by":"crossref","unstructured":"Spiller HA, Klein-Schwartz W, Colvin JM, Villalobos D, Johnson PB, Anderson DL. Toxic clonidine ingestion in children. J Pediatr.\u20082005;146(2):263\u2013266","DOI":"10.1016\/j.jpeds.2004.09.027"},{"key":"2021120822560191100_R6","doi-asserted-by":"crossref","unstructured":"Daubert GP. Is brimonidine ophthalmic a safe therapy for infants?J Clin Pharm Ther.\u20082006;31(3):289\u2013292","DOI":"10.1111\/j.1365-2710.2006.00734.x"},{"key":"2021120822560191100_R7","doi-asserted-by":"crossref","unstructured":"Walters G, Taylor RH. Severe systemic toxicity caused by brimonidine drops in an infant with presumed juvenile xanthogranuloma. Eye.\u20081999;13:797\u2013798","DOI":"10.1038\/eye.1999.235"},{"key":"2021120822560191100_R8","doi-asserted-by":"crossref","unstructured":"Korsch E, Grote A, Seybold M, Soditt V. Systemic adverse effects of topical treatment with brimonidine in an infant with secondary glaucoma. Eur J Pediatr.\u20081999;158(8):685","DOI":"10.1007\/PL00008324"},{"key":"2021120822560191100_R9","doi-asserted-by":"crossref","unstructured":"Carlsen JO, Zabriskie NA, Kwon YH, Barbe ME, Scott WE. Apparent central nervous system depression in infants after the use of topical brimonidine. Am J Ophthalmol.\u20081999;128(2):255\u2013256","DOI":"10.1016\/S0002-9394(99)00083-5"},{"key":"2021120822560191100_R10","doi-asserted-by":"crossref","unstructured":"Berlin RJ, Lee UT, Samples JR. Ophthalmic drops causing coma in an infant. J Pediatr.\u20082001;138(3):441\u2013443","DOI":"10.1067\/mpd.2001.111319"},{"key":"2021120822560191100_R11","unstructured":"Chu J, Nelson LS, Howland MA, et al. Apnea in an infant after intraocular administration of adult strength ophthalmic solutions for glaucoma. J Toxicol Clin Toxicol.\u20082001;39(3):304"},{"key":"2021120822560191100_R12","doi-asserted-by":"crossref","unstructured":"Prok L, Hall DA. 24-day old with episodic lethargy, hypotonia, and apnea. Curr Opin Pediatr.\u20082003;15(2):226\u2013228","DOI":"10.1097\/00008480-200304000-00015"},{"key":"2021120822560191100_R13","doi-asserted-by":"crossref","unstructured":"Mungan NK, Wilson TW, Nischal KK, et al. Hypotension and bradycardia in infants after the use of topical brimonidine and beta-blockers. J AAPOS.\u20082003;7(1):69\u201370","DOI":"10.1067\/mpa.2003.S1091853102420137"},{"key":"2021120822560191100_R14","doi-asserted-by":"crossref","unstructured":"Levy Y, Zadok D. Systemic side effects of ophthalmic drops. Clin Pediatr (Phila).\u20082004;43(1):99\u2013101","DOI":"10.1177\/000992280404300114"},{"key":"2021120822560191100_R15","doi-asserted-by":"crossref","unstructured":"Heimann K, Peschgens T, Merz U, Hoernchen H, Wenzl T. Depression of respiration via toxic effects on the central nervous system following use of topical brimonidine in an infant with congenital glaucoma. Ophthalmologe.\u20082007;104(6):505\u2013507","DOI":"10.1007\/s00347-006-1471-z"},{"key":"2021120822560191100_R16","doi-asserted-by":"crossref","unstructured":"Rangan C, Everson G, Cantrell FL. Central alpha-2 adrenergic eye drops: case series of 3 pediatric systemic poisonings. Pediatr Emerg Care.\u20082008;24(3):167\u2013169","DOI":"10.1097\/PEC.0b013e3181668aee"},{"key":"2021120822560191100_R17","doi-asserted-by":"crossref","unstructured":"Enyedi LB, Freedman SF. Safety and efficacy of brimonidine in children with glaucoma. J AAPOS.\u20082001;5(5):281\u2013284","DOI":"10.1067\/mpa.2001.117571"},{"key":"2021120822560191100_R18","doi-asserted-by":"crossref","unstructured":"Bowman RJC, Cope J, Nischal KK. Ocular and systemic side effects of brimonidine 0.2% eye drops (Alphagen) in children. Eye.\u20082004;18(1):24\u201326","DOI":"10.1038\/sj.eye.6700520"},{"key":"2021120822560191100_R19","doi-asserted-by":"crossref","unstructured":"Al-Shahwan S, Al-Torbak AA, Turkmani S, Al-Oman M, Al-Jadaan I, Edward D. Side-effect profile of brimonidine tartrate in children. Ophthalmology.\u20082005;112(12):2143\u20132148","DOI":"10.1016\/j.ophtha.2005.06.035"},{"key":"2021120822560191100_R20","doi-asserted-by":"crossref","unstructured":"Moore W, Nischal KK. Pharmacologic management of glaucoma in childhood. Paediatr Drugs.\u20082007;9(2):71\u201379","DOI":"10.2165\/00148581-200709020-00001"},{"key":"2021120822560191100_R21","unstructured":"Ali S, Chalut D, Senecal PE. Unintentional ingestion of brimonidine ophthalmic drops necessitating intubation. J Toxicol Clin Toxicol.\u20082001;39(5):501\u2013502"},{"key":"2021120822560191100_R22","doi-asserted-by":"crossref","unstructured":"Sztajnbok J. Failure of naloxone to reverse brimonidine-induced coma in an infant. J Pediatr.\u20082002;140(4):485\u2013486","DOI":"10.1067\/mpd.2002.120816"},{"key":"2021120822560191100_R23","doi-asserted-by":"crossref","unstructured":"Hoffmann U, Kuno S, Franke G, Fusch C, Haas JP. Adrenoceptor agonist poisoning after accidental oral ingestion of brimonidine eye drops. Pediatr Crit Care Med.\u20082004;5(3):282\u2013285","DOI":"10.1097\/01.PCC.0000123548.73664.18"},{"key":"2021120822560191100_R24","doi-asserted-by":"crossref","unstructured":"Soto-Pe\u0301rez-de-Celis E, Skvirsky DO, Cisneros BG. Unintentional ingestion of brimonidine antiglaucoma drops. Pediatr Emerg Care.\u20082007;23(9):657\u2013658","DOI":"10.1097\/PEC.0b013e31814b2df0"},{"key":"2021120822560191100_R25","unstructured":"Poisindex database (Brimonidine). Greenwood, CO: Micromedex Corporation (Thomson Science); 2008"},{"key":"2021120822560191100_R26","doi-asserted-by":"crossref","unstructured":"Tenenbein M. Naloxone in clonidine toxicity. Am J Dis Child.\u20081984;138(11):1084","DOI":"10.1001\/archpedi.1984.02140490084023"},{"key":"2021120822560191100_R27","doi-asserted-by":"crossref","unstructured":"Fiser DH, Moss MM, Walker W. Critical care for clonidine poisoning in toddlers. Crit Care Med.\u20081990;18(10):1124\u20131128","DOI":"10.1097\/00003246-199010000-00014"},{"key":"2021120822560191100_R28","doi-asserted-by":"crossref","unstructured":"Romano RJ, Dinh A. A 1000-fold overdose of clonidine caused by a compounding error in a 5-year-old child with attention-deficit\/hyperactivity syndrome. Pediatrics.\u20082001;108(2):471\u2013472","DOI":"10.1542\/peds.108.2.471"},{"key":"2021120822560191100_R29","doi-asserted-by":"crossref","unstructured":"Banner W, Lund ME, Clawson L. Failure of naloxone to reverse clonidine toxic effects. Am J Dis Child.\u20081983;137(12):1170\u20131171","DOI":"10.1001\/archpedi.1983.02140380030009"},{"key":"2021120822560191100_R30","doi-asserted-by":"crossref","unstructured":"Wedin GP, Richardson SL, Wallace GH. Clonidine poisoning in children. Am J Dis Child.\u20081990;144(8):853\u2013854","DOI":"10.1001\/archpedi.1990.02150320015011"},{"key":"2021120822560191100_R31","doi-asserted-by":"crossref","unstructured":"Litovitz T, Klein-Schwartz W, Rodgers G, et al. 2001 annual report of the American Association of Poison Control Centers toxic exposure surveillance system. Am J Emerg Med.\u20082002;20(5):391\u2013452","DOI":"10.1053\/ajem.2002.34955"},{"key":"2021120822560191100_R32","unstructured":"American Association of Poison Control Centers. Toxic Exposure Surveillance System Coding Instruction Manual. Washington, DC: American Association of Poison Control Centers; 2003"}],"container-title":["Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/123\/2\/e305\/1125035\/zpe0020900e305.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/123\/2\/e305\/1125035\/zpe0020900e305.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,9]],"date-time":"2021-12-09T02:51:44Z","timestamp":1639018304000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.aap.org\/pediatrics\/article\/123\/2\/e305\/69353\/Brimonidine-Tartrate-Poisoning-in-Children"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,2,1]]},"references-count":32,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2009,2,1]]},"published-print":{"date-parts":[[2009,2,1]]}},"URL":"https:\/\/doi.org\/10.1542\/peds.2008-1951","relation":{},"ISSN":["0031-4005","1098-4275"],"issn-type":[{"value":"0031-4005","type":"print"},{"value":"1098-4275","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,2,1]]}}}